The main risk is not whether AI demand exists; it is whether Core Scientific can convert demand into billable, financed, permitted capacity before concentration, leverage and timeline slippage give too much bargaining power to customers, lenders or regulators. Texas permissioning, project funding terms, and proof that leased
MW becomes live revenue remain the real gates between a
rerating and a stalled transition story.